Viromed Medical AG Secures Federal Funding for Cold Plasma Technology Development

Viromed Medical AG has received funding approval from the Federal Ministry of Research, Technology and Space for research and development projects in the field of cold plasma technology. The certification was granted under the Research Allowance Act (FZulG) and comprises funding in the high six-figure euro range. This financial support enables the company to advance two specific medical innovations that could address significant healthcare challenges.

The funding focuses on the further development of innovative medical systems for the application of cold atmospheric plasma, including a stationary system for integration into ventilation processes called PulmoPlas®. The aim is to selectively inactivate pathogenic germs in the lower respiratory tract and thereby enable new therapeutic approaches, particularly in intensive care medicine. This represents a novel approach for which no comparable systems currently exist, potentially offering a non-pharmacological alternative for treating respiratory infections.

In addition, the development of a mobile device for contact-free plasma application to support wound healing called ViroCap® is being funded. Both projects address key medical challenges and expand the current state of the art in medical technology. The funding underscores Viromed's strong innovative capabilities and confirms the scientific and technological relevance of its solutions. With this funding, Viromed is consistently advancing the development of PulmoPlas® and ViroCap® and strengthening its position in the field of non-pharmacological treatment of infectious diseases.

The company's progress can be followed through its official website at www.viromed-medical-ag.de. The funding approval represents a significant validation of cold plasma technology's potential in medical applications, particularly for addressing infections without relying solely on pharmaceutical interventions. This development matters because it could lead to new treatment options for patients in intensive care settings and those with chronic wounds, potentially reducing reliance on antibiotics and improving patient outcomes. The research could establish Germany as a leader in this emerging medical technology field while addressing growing concerns about antimicrobial resistance.